^
Association details:
| Biomarker: | DNMT3A deletion |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | BAY 1082439 (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of Dnmt3a Dysregulates Hematopoietic Homeostasis and Myeloid Skewing Via the PI3Kinase Pathway: PI3Ka/ß Inhibition Corrects Extramedullary Hematopoiesis and Myeloid Skewing Due to Loss of Dnmt3a
Published date:
11/06/2019
Excerpt:
We investigated the role of PI3Kinase signaling in Dnmt3a loss induced myeloid malignancy using pharmacological inhibitor, GDC0941 (PI3Kα/δ inhibitor) and BAY1082439 (PI3Kα/β inhibitor). PI3Kα/β inhibitor treatment of Dnmt3a-/- mice markedly reduced monocytosis, neutrophilia, enhanced WBC counts, and improved RBCs, hematocrits and platelet numbers compared to control mice....Consistent with this notion, PI3K inhibitor treatment of malignant Dnmt3a-/- bearing mice showed significantly improved overall survival compared to controls.
DOI:
https://doi.org/10.1182/blood-2019-131036
